High-confidence cancer patient stratification through multiomics investigation of DNA repair disorders.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
26 11 2022
26 11 2022
Historique:
received:
23
07
2022
accepted:
11
11
2022
revised:
10
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
Multiple cancer types have limited targeted therapeutic options, in part due to incomplete understanding of the molecular processes underlying tumorigenesis and significant intra- and inter-tumor heterogeneity. Identification of novel molecular biomarkers stratifying cancer patients with different survival outcomes may provide new opportunities for target discovery and subsequent development of tailored therapies. Here, we applied the artificial intelligence-driven PandaOmics platform ( https://pandaomics.com/ ) to explore gene expression changes in rare DNA repair-deficient disorders and identify novel cancer targets. Our analysis revealed that CEP135, a scaffolding protein associated with early centriole biogenesis, is commonly downregulated in DNA repair diseases with high cancer predisposition. Further screening of survival data in 33 cancers available at TCGA database identified sarcoma as a cancer type where lower survival was significantly associated with high CEP135 expression. Stratification of cancer patients based on CEP135 expression enabled us to examine therapeutic targets that could be used for the improvement of existing therapies against sarcoma. The latter was based on application of the PandaOmics target-ID algorithm coupled with in vitro studies that revealed polo-like kinase 1 (PLK1) as a potential therapeutic candidate in sarcoma patients with high CEP135 levels and poor survival. While further target validation is required, this study demonstrated the potential of in silico-based studies for a rapid biomarker discovery and target characterization.
Identifiants
pubmed: 36435816
doi: 10.1038/s41419-022-05437-w
pii: 10.1038/s41419-022-05437-w
pmc: PMC9701218
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
999Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2022 Aug 20;40(24):2735-2750
pubmed: 35649217
Mol Biol Cell. 2019 Mar 21;30(7):811-819
pubmed: 30699045
Cell. 1998 May 1;93(3):467-76
pubmed: 9590180
Trends Cell Biol. 2020 Feb;30(2):117-132
pubmed: 31917080
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14454-9
pubmed: 25249633
Nat Rev Mol Cell Biol. 2018 May;19(5):297-312
pubmed: 29363672
iScience. 2022 Apr 04;25(5):104190
pubmed: 35479398
N Engl J Med. 2018 Feb 1;378(5):491-492
pubmed: 29385361
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Front Genet. 2018 Jul 12;9:242
pubmed: 30050560
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
FASEB J. 2017 Jan;31(1):238-255
pubmed: 27733450
PLoS Comput Biol. 2021 Jul 14;17(7):e1009183
pubmed: 34260589
Trends Mol Med. 2019 Jul;25(7):595-611
pubmed: 31078431
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Biochem Soc Trans. 2011 Dec;39(6):1764-9
pubmed: 22103522
Aging Cell. 2021 Apr;20(4):e13329
pubmed: 33734555
Aging (Albany NY). 2013 Mar;5(3):192-208
pubmed: 23524341
Mol Biol Cell. 2019 May 1;30(10):1230-1244
pubmed: 30811267
Cells. 2020 Oct 14;9(10):
pubmed: 33066395
J Neurosci. 2005 Mar 9;25(10):2522-9
pubmed: 15758161
Signal Transduct Target Ther. 2021 Jul 9;6(1):254
pubmed: 34238917
Cell. 2017 Feb 9;168(4):644-656
pubmed: 28187286
Neuroscience. 2007 Apr 14;145(4):1300-8
pubmed: 17055654
Int J Cancer. 2008 Feb 15;122(4):802-6
pubmed: 17957789
Eur J Cancer. 2010 Aug;46(12):2206-15
pubmed: 20471824
Stem Cell Reports. 2014 Mar 27;2(4):534-46
pubmed: 24749076
Clin Genet. 2016 Aug;90(2):105-17
pubmed: 26662178
Nat Rev Dis Primers. 2019 Sep 19;5(1):64
pubmed: 31537806
Nat Rev Cancer. 2012 Dec;12(12):801-17
pubmed: 23175119
Curr Oncol. 2018 Apr;25(2):e176-e180
pubmed: 29719442
Nat Rev Cancer. 2015 May;15(5):276-89
pubmed: 25907220
Biochim Biophys Acta. 2007 Jan;1775(1):21-62
pubmed: 16904831
Oncoscience. 2018 Feb 23;5(1-2):21-38
pubmed: 29556515
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Oncotarget. 2017 Dec 28;9(8):7796-7811
pubmed: 29487692
Cell Cycle. 2017;16(17):1578-1584
pubmed: 28594262
Nat Rev Drug Discov. 2010 Mar;9(3):203-14
pubmed: 20168317
Aging (Albany NY). 2019 Aug 12;11(15):5786-5806
pubmed: 31408848
Orphanet J Rare Dis. 2011 Nov 01;6:70
pubmed: 22044607
J Med Chem. 2021 Mar 11;64(5):2382-2418
pubmed: 33650861
Signal Transduct Target Ther. 2021 Dec 20;6(1):424
pubmed: 34924562
J Cell Biol. 2014 Sep 29;206(7):855-65
pubmed: 25246616
Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):487-505
pubmed: 32393771
Aging (Albany NY). 2022 Mar 29;14(6):2475-2506
pubmed: 35347083
F1000Prime Rep. 2014 Apr 01;6:23
pubmed: 24765528
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Tumour Biol. 2013 Oct;34(5):2753-7
pubmed: 23765759
Cells. 2020 Dec 31;10(1):
pubmed: 33396222
Nat Rev Cancer. 2008 Mar;8(3):193-204
pubmed: 18256616
J Carcinog Mutagen. 2014;5:
pubmed: 25541596
Stem Cells Transl Med. 2012 Jul;1(7):523-35
pubmed: 23197857
Nat Commun. 2016 Nov 16;7:13427
pubmed: 27848968
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Sci Rep. 2017 Aug 8;7(1):7516
pubmed: 28790359
J Cell Biol. 2002 Jan 7;156(1):87-99
pubmed: 11781336
Front Aging Neurosci. 2022 Jun 28;14:914017
pubmed: 35837482
Front Cardiovasc Med. 2022 Mar 10;9:851491
pubmed: 35360042
Cell. 1999 Dec 10;99(6):577-87
pubmed: 10612394
Nat Rev Drug Discov. 2020 Aug;19(8):533-552
pubmed: 32528145
J Clin Immunol. 2015 Aug;35(6):538-49
pubmed: 26271390
Curr Med Chem. 2019;26(42):7655-7671
pubmed: 30027846
Cancer Genet Cytogenet. 1990 May;46(1):9-19
pubmed: 2184934
PLoS One. 2014 Jul 10;9(7):e101685
pubmed: 25010664
Nat Biotechnol. 2019 Sep;37(9):1038-1040
pubmed: 31477924
Front Oncol. 2021 Jul 16;11:677051
pubmed: 34336664